DOCSLIB.ORG

Inflammatory Bowel Disease: Current Treatment Strategies Edward V

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inflammatory Bowel Disease: Current Treatment Strategies Edward V Inflammatory Bowel Disease: Current Treatment Strategies Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. ©2010 MFMER | slide-1 Loftus Disclosures (last 12 months) • Research support • Consultant • AbbVie •AbbVie • UCB •UCB • Genentech •Janssen • Janssen •Takeda • Amgen •Bristol-Myers Squibb • Pfizer •Amgen • Takeda •Salix • Robarts Clinical Trials •CVS Caremark • Gilead •Eli Lilly • Receptos •Pfizer • Celgene • Seres Therapeutics • MedImmune Overview • Existing treatment paradigms for Crohn’s • Evolving paradigms • Risk stratification • Treating earlier in disease course • Measuring objective inflammation to base treatment • Objective treatment endpoints • Therapeutic drug monitoring • New therapies ©2010 MFMER | slide-3 Management of Crohn’s Disease Prednisone, Budesonide AZA/6MP/MTX Anti-TNF (Infliximab, Adalimumab, Certolizumab Induction pegol) Vedolizumab or Natalizumab AZA/MTX, Anti-TNF, Anti-Integrin Maint Lichtenstein GR, Hanauer SB, Sandborn WJ. Am J Gastroenterol 2009;104:465-83. Baumgart DC, Sandborn WJ. Lancet 2012;380:1590-1605. Evolving Treatment Paradigm Using Available Data for Risk Prognostication ©2010 MFMER | slide-5 Risk Factors Associated With Intestinal Complications: Crohn’s, Olmsted County Characteristic Hazard 95% CI Ratio Terminal ileum 7.8 3.5 – 17.4 Ileocolonic 5.6 2.3 – 13.9 Upper GI 9.5 3.0 – 30.1 Perianal fistula 1.7 0.99 – 2.86 Thia KT et al. Gastroenterology 2010;139:1147-55. AGA Clinical Pathway for Crohn’s Disease: Characterizing Risk Low Risk High Risk >30 years Age at diagnosis <30 years Anatomic Limited Extensive involvement Perianal and/or No severe Yes rectal disease Superficial Ulcers Deep Prior surgical No Yes resection Stricturing and/or No penetrating Yes Sandborn WJ. 7 Gastroenterology. 2014;147:702-705. behavior AGA Clinical Pathway for Crohn’s Disease: Initial Treatment Low-risk patient Moderate/high-risk patient Ileum and/or proximal colon, none to minimal symptoms Options Options • Anti-TNF monotherapy over no therapy • Budesonide 9 mg/day with or without AZA or thiopurine monotherapy • Tapering course of prednisone with or • Anti-TNF + thiopurine over thiopurine without AZA monotherapy or anti-TNF monotherapy • Methotrexate for patients who do not tolerate purine analog in combination with anti-TNF Diffuse or left colon, none to minimal symptoms Options • Tapering course of prednisone with or without AZA Sandborn WJ. Gastroenterology. 2014;147:702-705. 8 Efficacy of biologics in CROHN’S DISEASE 80 74.5 Clinical remission with induction therapy – only biologic-naïve patients 70 60 50 39.7 40 37.5 35.7 32.5 31.6 29.8 29.2 30 26.5 20 20 12.2 10 4 Clinical Remission with with InductionClinical therapy Remission (%) 0 Targan Lemann CLASSIC-1 Watanabe PRECISE-1 Sandborn Infliximab Adalimumab Certolizumab pegol ©2011 MFMER | slide-9 Crohn’s “Net Remission” at Six Months: Certolizumab, Adalimumab, Infliximab 1 Certolizumab Pegol – PRECISE 2 Infliximab – ACCENT I2 100 100 Pbo CzP Pbo IFX 80 80 64.1 58.5 60 47.9 60 39.0 40 40 28.6 30.7 22.8 18.3 21.0 20 20 12.3 % % of Patients % % of Patients 0 0 Open-label Week 26 Net Open-label Week 30 Net Induction remission remission Induction remission remission Week 6 week 26 Week 2 week 30 Certolizumab Pegol – PRECISE 14 Adalimumab - CHARM3 100.0 Pbo ADA 100 Pbo CzP 80.0 80 58.0 60.0 60 40.0 40.0 40 29.5 23.2 18.3 17.0 20 20.0 9.9 % % of Patients % % of Patients 0 0.0 Net Open Label Week 26 Net remission Induction remission remission week 26 Week 4 week 26 1. Schreiber et al. New Engl J Med 2007;357:239-250 2. Hanauer et al. Lancet 2002;359:1541-49 3. Colombel et al. Gastroenterology 2007;132:52-65 4. Sandborn et al. New Engl J Med 2007;357:228-38 Mucosal Healing With Adalimumab in CD (EXTEND) 50 ADA induction (160/80 mg)/placebo ADA QOW (40 mg) 40 P=0.056, NS P<0.001 30 27.4% 24.2% 20 13.1% Patients (%) Patients 10 0 8/61 17/62 0/61 15/62 0 Week 12 ITT Week 52 ITT ITT, intent-to-treat; NS, not significant Primary End Point Rutgeerts P et al. Gastroenterology. 2012;142:1102. Infliximab Effect on Hospitalizations and Surgeries – ACCENT I Crohn’s-related Hospitalizations Intra-abdominal Surgeries 40 38 7.4 35 8 7 30 24 6 25 23 23.5 5 20 4 3.1 2.9 15 3 2.6 10 2 5 1 Hospitalizations Per 100 Pts Hospitalizations 0 with (%) Surgeries Patients 0 Episodic 5 mg/kg 10 mg/kg Combined Episodic 5 mg/kg 10 mg/kgCombined Rutgeerts P, et al. Gastroenterology. 2004;126:402-13. Infliximab Prevents Endoscopic Recurrence in Post-Operative Crohn’s disease (PREVENT) Compare the efficacy of IFX with PBO in the prevention of clinical and endoscopic recurrence of CD following ileocolonic resection (randomized ≤45 days from surgery) Clinical recurrence=composite of CDAI>200, >70 pt increase, and endoscopic recurrence (Rutgeerts ≥i2) Regueiro M et al, Gastroenterology 2016;150:1568-78. Infliximab Prevents Endoscopic Recurrence in Post-Operative Crohn’s disease (PREVENT) Technically a negative study since primary endpoint not met, but infliximab reduced endoscopic recurrence by ≥50% Risk factors for clinical recurrence: Prior anti-TNF exposure >1 resection Regueiro M et al, Gastroenterology 2016;150:1568-78. SONIC: Corticosteroid-Free Clinical Remission at Week 26 Primary Endpoint 100 p<0.001 80 p=0.009 p=0.022 60 56.8 44.4 40 30.6 20 Proportion of Patients (%) 52/170 75/169 96/169 0 AZA + placebo IFX + placebo IFX+ AZA Colombel JF, et al. N Engl J Med. 2010;362:1383-1395. Infliximab vs Infliximab/MTX for Crohn’s-COMMIT Trial • Crohn’s patients in flare on steroids • Fixed steroid taper • All pts IFX 5 mg/kg usual induction/maintenance • Randomized to MTX or placebo (10 mg increased to 25 mg weekly • Primary endpoint: time to treatment failure (failure to • Negative study achieve steroid-free remission at week 14 or • Because all pts failure to maintain this thru week 50 received steroids? Feagan BG et al, Gastroenterology 2014; 146:681-8. Indirect Treatment Comparison Network Meta-analysis of Biologics in Biologic-Naïve Crohn’s Disease Patients • Infliximab (IFX) may be superior to certolizumab pegol (CZP), but is comparable to adalimumab (ADA) for induction of remission • All agents are comparable for maintenance of remission Singh et al. Mayo Clin Proc 2014;89:1621 ©2011 MFMER | slide-17 Limitations of Network Meta-analysis • Differences in trial design – no trial of standard IFX induction therapy • Differences in co-interventions • Indirect comparisons with no head-to-head trials – decreases quality of evidence • All short-term trials of induction and 1-year maintenance therapy • No data on long-term patient-relevant outcomes (hospitalization, surgery, etc.) • Registration trials, with restrictive inclusion criteria – not real-world experience ©2011 MFMER | slide-18 Infliximab vs. Adalimumab for Crohn’s disease U.S. Medicare Database • Retrospective cohort, 2006-2010 • Biologic-naïve adults with CD, treated with IFX (n=1459) vs. ADA (n=871) Outcome of Interest Adjusted HR (95% CI) IFX vs. ADA Hospitalization 0.88 (0.72-1.07) Surgery 0.79 (0.60-1.05) • Limitations • Older cohort – 44.2% >60y old • In patients younger than 65y, IBD-related surgery IFX vs. ADA – OR, 0.66 (0.47-0.93) Osterman et al. Clin Gastroenterol Hepatol 2014;12:811 ©2011 MFMER | slide-19 Infliximab vs. Adalimumab-Crohn’s Risk of IBD-RELATED HOSPITALIZATION Adjusted HR (IFX vs. ADA): 0.80 (0.66-0.98) % of patients free of event date after index of patients free of event % Singh et al. Presented at DDW; May 19, 2015; Abstract 922 ©2011 MFMER | slide-20 Infliximab vs. Adalimumab-Crohn’s Risk of ABDOMINAL SURGERY Adjusted HR (IFX vs. ADA): 0.76 (0.58-0.99) % of patients free of event date after index % of patients free of event Singh et al. Presented at DDW; May 19, 2015; Abstract 922 ©2011 MFMER | slide-21 Infliximab for UC: ACT 1 and ACT 2 Clinical Remission ACT 1 ACT 2 Placebo IFX 5 mg/kg IFX 10 mg/kg Placebo IFX 5 mg/kg IFX 10 mg/kg ‡ 45 § † ‡ † § 40 39 † § 36 40 ‡ 37 34 ‡ 34 35 34 35 35 32 30 28 30 26 25 25 20 20 16 17 15 15 15 11 10 10 6 Percent of Patients Percent 5 of Patients Percent 5 0 0 8 Weeks 30 Weeks 54 Weeks 8 Weeks 30 Weeks † P 0.002 vs placebo ‡ P 0.003 vs placebo § P = 0.001 vs placebo Rutgeerts P et al. N Engl J Med 2005;353:2462-76 ACT1/2 Trials: Survival Free of Colectomy Sandborn WJ et al, Gastroenterology 2009;137:1250-60. UC SUCCESS Trial: Combination IFX/AZA Vs. Monotherapy in Moderate to Severe UC – Week 16 90% * * P < 0.05 vs AZA * ** P<0.05 vs AZA and vs IFX 80% 77% 69% * 70% * 63% 60% 55% 50% 50% ** AZA 40% 40% 37% IFX AZA + IFX 30% 24%22% 20% 10% 0% Steroid-free Response Mucosal healing remission Conclusion: IFX+AZA superior to both AZA and IFX monotherapy in inducing steroid-free remission Panaccione R et al, Gastroenterology 2014;146:392-400. Adalimumab for Moderate to Severe UC: Induction/Maintenance Trial (n=494) Week 8 Endpoints Week 52 Endpoints 60% ** 60% 50.4% * 50% 50% 41.1% 40% 34.6% 40% * 31.7% * Placebo 30.2% Placebo 30% * 30% ** 25.0% ADA 18.3% ADA 20% 16.5% 20% 17.3% 15.4% 9.3% 8.5% 10% 10% 0% 0% * p<0.05 Mucosal healing ** p<0.005 Clinical remissionClinical response Mucosal healing Clinical remissionClinical response Sandborn WJ et al, Gastroenterology 2012;142:257-65.
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • List Item PDCO Monthly Report of Opinions on Paediatric Investigation
    10 November 2017 EMEA/PDCO/754430/2017 Inspections, Human Medicines Pharmacovigilance and Committees Division PDCO monthly report of opinions on paediatric investigation plans and other activities 7 - 10 November 2017 Opinions on paediatric investigation plans The Paediatric Committee (PDCO) adopted opinions agreeing paediatric investigation plans (PIPs) for the following medicines: • Vosoritide, EMEA-002033-PIP01-16, from BioMarin International Limited, for the treatment of achondroplasia; • Risankizumab, EMEA-001776-PIP02-17, from AbbVie Ltd, for the treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis); • Brazikumab, EMEA-001929-PIP01-16, from Allergan Limited, for the treatment of Crohn's disease and for the treatment of ulcerative colitis; • Trazodone (hydrochloride), EMEA-002142-PIP01-17, from Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A, for the treatment of insomnia; • Susoctocog alfa, EMEA-000753-PIP02-16, from Baxalta Innovations GmbH, for the treatment of congenital haemophilia A with antibodies (inhibitors) to human factor VIII; • Carotuximab, EMEA-002138-PIP01-17, from TRACON Pharma Limited, for the treatment of soft tissue sarcoma; • Budesonide / glycopyrronium bromide / formoterol (fumarate), EMEA-002063-PIP01-16, from Pearl Therapeutics, Inc., for the treatment of asthma; • Fremanezumab, EMEA-001877-PIP03-17, from Teva Pharma GmbH, for prevention of cluster headache • Cemiplimab, EMEA-002007-PIP02-17, from Regeneron Ireland U.C., for the treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) A PIP sets out a programme for the development of a medicine in the paediatric population. The PIP 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5510 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2017.
    [Show full text]
  • TNF-Anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages Via an Fc-Dependent Mechanism
    UvA-DARE (Digital Academic Repository) Macrophages as a therapeutic target in inflammatory bowel disease Lessons learned from anti-TNF therapy Houttuijn Bloemendaal, F.M. Publication date 2020 Document Version Other version License Other Link to publication Citation for published version (APA): Houttuijn Bloemendaal, F. M. (2020). Macrophages as a therapeutic target in inflammatory bowel disease: Lessons learned from anti-TNF therapy. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:30 Sep 2021 CHAPTER 3 TNF-anti-TNF immune complexes inhibit IL-12/IL-23 secretion by inflammatory macrophages via an Fc-dependent mechanism Felicia M. Bloemendaal, Pim J. Koelink, Karin A. van Schie, Theo Rispens, Charlotte P. Peters, Christianne J. Buskens, Jarmila D. van der Bilt, Willem.
    [Show full text]
  • The Current State of the Art for Biological Therapies and New Small Molecules in Inflammatory Bowel Disease
    www.nature.com/mi REVIEW ARTICLE The current state of the art for biological therapies and new small molecules in inflammatory bowel disease Sudarshan Paramsothy1, Adam K. Rosenstein1,2, Saurabh Mehandru1,2 and Jean-Frederic Colombel1 The emergence of biologic therapies is arguably the greatest therapeutic advance in the care of inflammatory bowel disease (IBD) to date, allowing directed treatments targeted at highly specific molecules shown to play critical roles in disease pathogenesis, with advantages in potency and selectivity. Furthermore, a large number of new biologic and small-molecule therapies in IBD targeting a variety of pathways are at various stages of development that should soon lead to a dramatic expansion in our therapeutic armamentarium. Additionally, since the initial introduction of biologics, there have been substantial advances in our understanding as to how biologics work, the practical realities of their administration, and how to enhance their efficacy and safety in the clinical setting. In this review, we will summarize the current state of the art for biological therapies in IBD, both in terms of agents available and their optimal use, as well as preview future advances in biologics and highly targeted small molecules in the IBD field. Mucosal Immunology (2018) 11:1558–1570; https://doi.org/10.1038/s41385-018-0050-3 INTRODUCTION concerns regarding the safety of these agents have decreased Inflammatory bowel disease (IBD) incorporates a spectrum of with accumulating data. Although there is a slightly increased risk chronic, often progressive and disabling, inflammatory disorders of serious infections, this is lower than initially predicted and less of the gastrointestinal tract including Crohn’s disease (CD) and than the risk associated with steroid use.12 Concerns regarding ulcerative colitis (UC).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • 211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
    211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease The impact of biological interventions on health-related quality of life in adults with Crohn's disease Protocol information Review type: Intervention Review number: 211 Authors Mirjana Stanic Benic1, Vanja Giljaca2, Vera Vlahovic-Palcevski1 1Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Rijeka, Croatia 2Directorate of Surgery, Department of Gastroenterology, Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, UK Citation example: Stanic Benic M, Giljaca V, Vlahovic-Palcevski V. The impact of biological interventions on health- related quality of life in adults with Crohn's disease. Cochrane Database of Systematic Reviews , Issue . Art. No.: . DOI: . Contact person Mirjana Stanic Benic resident in clinical pharmacology and toxicology Department of Clinical Pharmacology Clinical Hospital Centre Rijeka Krešimirova 42 Rijeka 51000 Croatia E-mail: [email protected] Dates Assessed as Up-to-date:Not provided Date of Search: Not provided Next Stage Expected: 28 February 2019 Protocol First Published:Not specified Review First Published: Not specified Last Citation Issue: Not specified What's new Date Event Description History Date Event Description Abstract Background Objectives Search methods Selection criteria Data collection and analysis Main results Authors' conclusions Plain language summary [Summary title] [Summary text] Background Description of the condition 1 / 20 211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease Crohn’s disease (CD) is a relapsing-remitting transmural inflammatory bowel disease (IBD) that may involve any part of the gastrointestinal tract from mouth to anus as well as cause extraintestinal manifestations (skin lesions, arthritis).
    [Show full text]
  • New Targets in Inflammatory Bowel Disease Therapy: 2021
    REVIEW CURRENT OPINION New targets in inflammatory bowel disease therapy: 2021 Nathaniel A. Cohen and David T. Rubin Purpose of review In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD). Recent findings Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn’s disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies. Summary The IBD physicians’ therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care. Keywords biologics, inflammatory bowel disease, new therapeutics, small molecules INTRODUCTION physician’s armamentarium, a significant percentage The inflammatory bowel diseases (IBD) are a hetero- of patients do not respond to these treatments [10]. geneous group of conditions divided into two As such, new treatment pathways and a greater predominant groups, Crohn’s disease (CD) and ulcer- understanding of mechanisms of treatment failure ative colitis (UC). These conditions are characterized are required. This will provide more options for by a chronic, progressive, or relapsing and remitting patients and greater individualization in treatment disease course with the gastrointestinal (GI) tract decision-making. being the major site of inflammatory activity. This review examines the future of IBD treat- Unchecked, this inflammation can result in a ments and details current phase I, II, and III clinical complicated disease course with undesirable ramifi- trial results.
    [Show full text]